Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NANP Targeting Radio-sensitizes Glioblastoma through TNFR1 Sialylation-Driven Mesenchymal Shift

ABSTRACT: GBM remains a highly devasting brain tumor mainly due to the resistance to radiotherapy (RT), the most impactful first-line treatment for GBM. Our clonal evolution study reveals no dominant RT-resistant clones to target for recurrence prevention, leading us for a genome-wide CRISPR screening for radio-sensitizing targets in GBM. The screening highlighted DNA damage response genes, particularly in the non-homologous end-joining (NHEJ) pathway, such as PRKDC and NHEJ1, as potent radio-sensitizers. Additionally, NANP (N-acylneuraminate-9-phosphatase), a critical enzyme in the sialic acid synthetic pathway, was identified as a novel RT-sensitizing target associated with patient outcomes. NANP knockdown induces increased G2/M arrest and apoptosis following radiation, with γH2AX staining and comet assays indicating greater DNA damage. NANP deficiency impairs DNA repair, favoring error-prone NHEJ over homologous recombination (HR). Mechanistically, NANP modulates the sialylation of TNFR1, thereby influencing NF-kB signaling and the mesenchymal (MES) state of glioma stem cells (GSCs), which consequently affects RT sensitivity. Intracranial orthotopic xenograft experiments validate the function of NANP in vivo. In summary, our findings identify NANP as a novel radio-sensitizing target, dependent on TNFR1 sialylation and MES shift, providing a basis for developing innovative RT sensitizers for GBM.

ORGANISM(S): Homo sapiens

PROVIDER: GSE274135 | GEO | 2025/12/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A Proneural to Mesenchymal Transition Mediated by NFkB Promotes Radiation Resistance in Glioblastoma (part 2)

Project description:SUMMARY Despite numerous genome-wide association studies involving glioblastoma (GBM), few therapeutic targets have been identified for this disease. Using patient derived glioma sphere cultures (GSCs), we have found that a subset of the proneural (PN) GSCs undergo transition to a mesenchymal (MES) state in a TNFa/NFkB dependent manner with an associated enrichment of CD44 sub-populations and radio-resistant phenotypes. To the contrary, MES GSCs exhibit constitutive NFkB activation, CD44 enrichment and radio-resistance. Patients whose tumors exhibit a higher MES metagene, increased expression of CD44, or activated NFkB were associated with poor radiation response and shorter survival. Our results indicate that NFkB activation mediated MES differentiation and radiation resistance presents an attractive therapeutic target for GBM. SIGNIFICANCE In this study, we show plasticity between the proneural (PN) and mesenchymal (MES) transcriptome signatures observed in glioblastoma (GBM). Specifically, we show that PN glioma sphere cultures (GSCs) can be induced to a MES state with an associated enrichment of CD44 expressing cells and a gain of radio-resistance, which we implicate as NFkB- dependent. Newly diagnosed GBM samples show a direct correlation between radiation response, higher MES metagene, CD44 expression, and NFkB activation. This correlation is also observed in the subset of GBM samples that do not exhibit IDH1 mutation, a favorable prognostic marker. Our results uncover a previously unknown link between subtype plasticity that is regulated by NFkB. Inhibition of NFkB activation can directly impact radio-resistance and presents an attractive therapeutic target for GBM. 4 treatments

2013-08-15 | E-GEOD-49162 | biostudies-arrayexpress

A Proneural to Mesenchymal Transition Mediated by NFkB Promotes Radiation Resistance in Glioblastoma (part 1)

2013-08-15 | E-GEOD-49161 | biostudies-arrayexpress

A Proneural to Mesenchymal Transition Mediated by NFkB Promotes Radiation Resistance in Glioblastoma (part 1)

2013-08-15 | GSE49161 | GEO

A Proneural to Mesenchymal Transition Mediated by NFkB Promotes Radiation Resistance in Glioblastoma (part 2)

2013-08-15 | GSE49162 | GEO

NANP Targeting Radio-sensitizes Glioblastoma through TNFR1 Sialylation-Driven Mesenchymal Shift

Project description:NANP Targeting Radio-sensitizes Glioblastoma through TNFR1 Sialylation-Driven Mesenchymal Shift

| PRJNA1145082 | ENA

BEAS-2B cells: Control versus chemical exposure

Project description:Transcriptonal profiling of BEAS-2B cells: Control versus skin sensitizers; Control versus respiratory sensitizers; Control versus non-sensitizing irritants

2013-12-01 | GSE44729 | GEO

BEAS-2B cells: Control versus chemical exposure

Project description:Transcriptonal profiling of BEAS-2B cells: Control versus skin sensitizers; Control versus respiratory sensitizers; Control versus non-sensitizing irritants Replicates: 3 biological replicates; Exposure: 10 different chemicals versus solvent, 1 exposure concentration (IC20); Exposure time: 3 different exposure time points;

2013-12-01 | E-GEOD-44729 | biostudies-arrayexpress

A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogeniccell death

Project description:Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that co- ordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 is required to trigger cell death, its non-catalytic scaffold function mediates strong pro-survival signaling. Accordingly, cancer cells can hijack RIPK1 to block necroptosis and evade immune detection. We generated a small-molecule proteolysis-targeting chimera (PROTAC) that selectively degraded human and murine RIPK1. PROTAC-mediated depletion of RIPK1 deregulated TNFR1 and TLR3/4 signaling hubs, accentuating the output of NF-kB, MAPK, and IFN signaling. Additionally, RIPK1 degradation simultaneously promoted RIPK3 activation and necroptosis induction. We further demonstrated that RIPK1 degradation enhanced the immunostimulatory effects of radio- and immunotherapy by sensitizing cancer cells to treat- ment-induced TNF and interferons. This promoted ICD, antitumor immunity, and durable treatment responses. Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radio- or immunotherapy resistance and enhance anticancer therapies.

2024-05-23 | PXD043560 | Pride

Serine/Threonine kinase MLK4 determines Mesenchymal identify in glioma stem cells in an NFkB-dependent manner

Project description:Activation of NF-kB induces MES trans-differentiation and radio-resistance in glioma stem cells (GSCs), but molecular mechanisms for NF-kB activation in GSCs are currently unknown. Here we report that Mixed Lineage Kinase 4 (MLK4) is overexpressed in MES but not PN GSCs. Silencing MLK4 suppresses self-renewal, motility, tumorigenesis, and radio-resistance of MES GSCs via a loss of the MES signature. MLK4 binds and phosphorylates the NF-κB regulator IKKα, leading to activation of NF-κB signaling in GSCs. MLK4 expression is inversely correlated with patient prognosis in MES, but not PN high-grade gliomas. Collectively, our results uncover MLK4 as an upstream regulator of NF-kB signaling and a potential molecular target for the MES subtype of GBMs. We used microarrays to validate MLK4 target gene expression.

2017-09-01 | GSE75224 | GEO

GSC 2907 SRGN IP mass spectrometry

Project description:Glioblastoma (GBM) is a highly lethal primary malignant brain tumor. The high level of heterogeneity within GBM inevitably leads to treatment resistance and tumor recurrence. Glioblastoma stem cells (GSCs) contribute to the distinct properties of GBM through their contribution to therapeutic resilience. Here, we found that enhanced classical (CL) and mesenchymal (MES) transcriptional signatures were associated with poor patient prognosis. Through the integrated analyses of single-cell RNA sequencing and clinical datasets, we identified specific brain tumor targets, including MEOX2 for the CL subtype and SRGN for the MES subtype respectively. MEOX2 sustained the CL subtype signature and played a particular role in CL GSCs by activating Notch signaling. SRGN maintained the MES phenotype and regulated the NF-κB signaling by preventing NFKB1 from proteasomal degradation. Both genetic and pharmacologic treatments showed that CL GSCs were preferentially sensitive to the inhibition of MEOX2, while MES GSCs were more susceptible to SRGN. We further screend FDA-approved drugs with MEOX2 and SRGN targeting capabilities as candidates for further investigation. Combined CL and MES targeting demonstrated enhanced efficacy, both in vitro and in vivo. Collectively, our results elucidated the mechanism of GBM heterogeneity, and highlighted a therapeutic strategy for the elimination of heterogeneous cellular populations through combinatorial targeting of MEOX2 and SRGN in GSCs.

2025-05-07 | PXD061009 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data